#WHO, #Antibacterialagents, #antibiotics, #UnitedNations, #pathogens,
Toronto, Sept 22 (Canadian-Media): World Health Organization (WHO) confirmed in a report – 'Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis' – acute shortage of new antibiotics to fight against growing threat of antimicrobial resistance.
Image credit: Official logo
WHO, established in 1948 and headquartered in Geneva, Switzerland -- is a specialized agency of the United Nations that is concerned with international public health.
Most of the drugs currently in the clinical pipeline, continued WHO report, were only short-term solutions as were in fact modifications of existing classes of antibiotics.
Antibiotics also called antibacterials, are drugs used in the treatment and prevention of bacterial infections either by killing or inhibit the growth of bacteria.
The serious lack of antibiotics in the world had left WHO with very few treatment options for those antibiotic-resistant infections, which WHO had identified.
This fact has posed greatest threat to health including drug-resistant tuberculosis which has resulted in around 250,000 fatalities each year..
Besides, multidrug-resistant tuberculosis, WHO reported that it had identified 12 classes of priority pathogens -- a microorganism-- that can cause disease, although some of these have side effects such as pneumonia or urinary tract infections.
Multidrug-resistant tuberculosis -- an infectious bacterial disease characterized by the growth of nodules (tubercles) in the tissues, especially the lungs -- along with newly identified priority pathogens are increasingly resistant to existing antibiotics and WHO is urgently in need of new treatments.